JP Morgan Maintains Neutral on IGM Biosciences, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains a Neutral rating on IGM Biosciences (NASDAQ:IGMS) and raises the price target from $11 to $12.
August 15, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Eric Joseph maintains a Neutral rating on IGM Biosciences and raises the price target from $11 to $12.
The raised price target from $11 to $12 indicates a positive outlook, albeit with a Neutral rating. This could lead to a slight positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100